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Colleen Delaney1,2Growing evidence supports the efficacy of cord blood transplantation (CBT), and the number of CBTs is
increasing. Numerous studies confirm the presence of a graft-versus-leukemia (GVL) effect following
CBT, and preliminary data suggests that double-unit CBT may be associated with a decreased risk of relapse.
We have observed a low relapse rate following CBT among patients with acute leukemias in morphologic
complete remission (CR) at the time of myeloablative (MA) transplant. To further assess this observation,
we conducted a matched cohort analysis comparing relapse rates and outcomes for patients receiving
CBTs versus patients receiving matched unrelated donor (MURD) and mismatched unrelated donor
(MMURD) transplants at our center. Thirty-one consecutive CBT patients (aged 0.6-42 years, median 22
years), transplanted between April 2006 and June 2008, were compared to matched subjects selected on
the basis of disease type and remission number, cytogenetic risk status, minimal residual disease status
(MRD), time from diagnosis to first relapse (for patients beyond CR1), use of imatinib for chronic myelo-
genous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) patients,
age, and date of transplant. With a median follow-up among surviving CBT patients of 21.1 months (range:
6.6-32.6 months), there has been 1 relapse among cord patients versus 8 relapses among MURD patients
(P5.018) and 7 relapses among MMURD patients (P5.019). Treatment-related mortality (TRM) between
cohorts is comparable. Although we have observed a high incidence of acute graft-versus-host disease
(aGVHD) following CBT, the incidence of National Institutes of Health (NIH) consensus criteria chronic
GVHD (cGVHD) has been low. These data support increased investigation of the use of CBT.
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Cord blood transplantation (CBT) is rapidly
evolving, and the number of CBTs is increasing.
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6/j.bbmt.2009.05.014decreased treatment-related mortality (TRM), and the
introduction of double-unit transplants has improved
engraftment rates and appears to have improved out-
comes among adults and large children [1-5]. Growing
inventories of higher quality cord units should con-
tinue to result in improved outcomes. Reports of lower
incidences of chronic graft-versus-host disease (cGV-
HD) and more treatment responsive GVHD com-
pared to other donor sources further enhance the
appeal of CBT [6-8]. Relative delays in immune
reconstitution and prolonged time to engraftment,
however, remain important challenges.
Despite improvements in TRM following CBT
and hematopoietic cell transplantion (HCT) in gen-
eral, disease relapse remains a prominent cause of death
following allogeneic transplant. As nontransplant-
based therapies improve, the relapse risk of patients
for whom HCT is indicated will likely increase, and
strategies to reduce relapse are crucial.Multiple studies
Biol Blood Marrow Transplant 15:1122-1129, 2009 1123Low Relapse without TRM following Myeloablative CBTconfirm the potency of the graft-versus-leukemia
(GVL) effect following CBT.Numerous series includ-
ing patients with heterogeneous status of disease at the
time of transplant suggest a comparable if not lower
risk of relapse following CBT compared to HCT
with other donor sources [7,9-14]. A growing body of
evidences suggests that, especially among patients
with good disease control at the time of transplant,
double-unit CBT may be associated with particularly
low relapse rates [3,15,16]. To evaluate relapse rates
following CBT, we conducted a matched cohort anal-
ysis comparing relapse rates and outcomes for patients
with acute leukemias in morphologic complete remis-
sion (CR) at the time of transplant receivingmyeloabla-
tive (MA) CBTs, matched unrelated donor (MURD)
transplants, and mismatched unrelated donor
(MMURD) transplants at our center.PATIENTS AND METHODS
Patients
Between April 2006, when our current cord blood
protocols opened, and June 2008, 31 consecutive
patients underwent MA CBT for acute leukemias in
morphologic CR (n5 29) or chronic myelogenous
leukemia (CML) not in blast crisis (n5 2). Results
were analyzed through December 2008. To provide
cohorts of MURD and MMURD subjects that were
as comparable as possible, 1 of each type of patient
was selected from our center’s database for each
CBT patient without knowledge of transplant out-
come. Potentially matched subjects were selected first
on the basis of disease status including disease type and
remission number, cytogenetic risk status, minimal
residual disease (MRD) status, time from diagnosis
to first relapse (for patients beyond CR1), and use of
imatinib for CML and Philadelphia chromosome-
positive acute lymphobalstic leukemia (ALL) patients.Table 1. Patient Characteristics
Cord
Number 31
Age 22 (0.6-42)
Disease AML n5 17
ALL n5 13
Biphenotypic n5 1
CML n5 2
Donor source Cord blood n5 31
Matching 4/6:4/6 n5 14
4/6:5/6 n5 5
5:6:5/6 n5 7
6/6:6/6 n5 1
5/6 n5 4
Conditioning Cy/TBI/Flu n5 31
MURD indicates matched unrelated donor; MMURD, mismatched unrelated d
kemia; CML, chronic myeloid myelogenous leukemia; Cy, cyclophosphamide; TMRDwas defined as the presence of detectable disease
by flow cytometry, cytogenetic analysis, or fluorescein
in situ hybridization (FISH) in patients with \5%
morphologic marrow blasts. From strata of subjects
matched on the above characteristics, final cohorts
were then selected based on closest possible matching
of age, date of transplant, and, for patients in CR1 at
the time of transplant, time from diagnosis to trans-
plant. All patients signed consent forms and this study
was approved by the center’s institutional review
board. General patient details are summarized below
and in Table 1. Details of individual matched pairs
are summarized in Table 2.
Among CBT patients, 27 patients received 2 units
(6 of whom had 1 of the 2 units CD341 selected and ex
vivo expanded) and 4 received single units. Matching
was performed at low resolution for HLA-A and -B
and high resolution (allele level) for HLA-DRB1.
Matching details are summarized in Table 1. For pa-
tients receiving CBT with unmanipulated units, sin-
gle-unit CBT was permitted for 6/6 units with total
nucleated cell count (TNC) $3.0 107/kg, 5/6 units
with TNC $4.0 107/kg, and 4/6 units with TNC
$6.0 107/kg. If these thresholds were not met, dou-
ble-unit CBT was performed and each unit was
required to have a TNC $1.5 107/kg. For patients
receiving an ex vivo expanded unit, the unmanipulated
unit was required to have a TNC$2.5 107/kg. Con-
ditioning regimen for 30 patients was 120 mg/kg
cyclophosphamide (Cy), 75 mg/m2 fludarabine (Flu),
and 13.2 Gy total body irradiation (TBI). One CBT
patient received decreased Cy dosing of 90 mg/kg
because of a history of liver abnormalities and esopha-
geal varices. For all CBT patients, GVHD prophylaxis
was cyclosporine (CsA) and mycophenolate mofetil
(MMF).
For unrelated donors, allele levelmatchingwas per-
formed at HLA-A,-B, -C, -DRB1, and -DQ. Among
MURD patients, transplants occurred betweenMMURD MURD
31 31
25 (1-48) 25 (0.9-41)
AML n5 18 AML n5 18
ALL n5 11 ALL n5 13
Biphenotypic n5 2 Biphenotypic n5 0
CML n5 2 CML n5 2
Bone marrow n5 15 Bone marrow n5 6
Peripheral blood n5 16 Peripheral blood n5 25
9/10 n5 28 10/10 n5 31
8/10 n5 3
Cy/TBI based n5 21 Cy/TBI based n5 24
Bu/Cy based n5 10 Bu/Cy based n 5 5
TREO/Flu n5 2
onor; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leu-
BI, total body irridiation; Flu, fludarabine; Bu, busulfan; TREO, treosulfan.
Table 2. Individual Cases and Matched Pairs
AML CR1/CML ALL CR1 AML/ALL beyond CR1
Donor Age Dx Dx status Transplant date Age Dx Dx status Transplant date Age Dx Dx status Days dx to relapse Transplant date
Cord 22 AML CR1 5/24/2007 0.6 B ALL CR1 11/1/2006 30 AML CR2 456 10/18/2007
MMURD 25 AML CR1 9/9/2004 1 B ALL CR1 11/1/2005 37 AML CR2 674 6/7/2005
MURD 26 AML CR1 9/7/2007 1 B ALL CR1 8/24/2006 29 AML CR2 717 11/23/2004
Cord 11 AML CR1 11/17/2007 14 B ALL CR1 10/5/2007 38 AML CR2 229 1/5/2007
MMURD 22 AML CR1 7/15/2004 8 B ALL CR1 2/23/2008 48 AML CR2 244 12/21/2004
MURD 18 AML CR1 8/30/2006 13 T ALL CR1 6/17/2006 40 AML CR2 313 5/19/2004
Cord 31 AML CR1 6/26/2006 22 T ALL CR1 1/17/2008 29 AML CR2 305 6/23/2008
MMURD 44 AML CR1 7/13/2006 10 T ALL CR1 10/8/2003 24 AML CR2 201 11/23/2002
MURD 29 AML CR1 6/16/2003 20 B ALL CR1 10/12/2007 30 AML CR2 489 5/4/2005
Cord 20 AML CR1 10/20/2006 0.9 B ALL CR1 5/16/2008 14 AML CR2 598 12/22/2006
MMURD 26 AML CR1 2/6/2004 2 B ALL CR1 - MRD 9/28/2006 25 AML CR2 456 5/14/2003
MURD 17 AML CR1 7/22/2003 0.9 B ALL CR1 2/28/2003 17 AML CR2 670 9/12/2005
Cord 30 AML CR1 11/22/2006 38 B ALL CR1 - MRD 8/11/2006 42 AML/MDS CR2 531 10/9/2006
MMURD 30 AML CR1 8/31/2006 39 Biphenotypic CR1 7/26/2006 44 AML CR2 365 2/15/2003
MURD 30 AML CR1 1/6/2005 38 B ALL CR1 - MRD 6/27/2007 31 AML CR2 366 12/10/2004
Cord 3 AML CR1 4/21/2006 21 B ALL CR1 4/17/2006 39 AML CR2 - MRD 391 10/3/2007
MMURD 8 AML CR1 10/18/2002 22 Biphenotypic CR1 6/11/2005 37 AML CR2 - MRD 306 7/9/2004
MURD 6 AML CR1 10/18/2005 25 B ALL CR1 10/1/2005 39 AML CR2 - MRD 628 12/21/2002
Cord 42 AML CR1 7/27/2006 23 ALL Ph+ CR1 - MRD 10/30/2006 5 B ALL CR3 - MRD 1038 12/18/2006
MMURD 45 AML CR1 12/6/2005 25 ALL Ph+ CR1 - MRD 3/9/2006 25 B ALL CR3 - MRD 1492 4/13/2007
MURD 40 AML CR1 7/16/2007 37 ALL Ph+ CR1 - MRD 7/29/2003 8 B ALL CR2 - MRD 1067 5/16/2007
Cord 26 Biphenotypic CR1 6/5/2008 28 ALL Ph+ CR1 - MRD 2/4/2008 2 B ALL CR2 - MRD 214 6/18/2007
MMURD 26 AML CR1 2/7/2003 38 ALL Ph+ CR1 - MRD 9/7/2006 22 B ALL CR2 - MRD 177 2/20/2004
MURD 21 AML CR1 5/2/2002 39 ALL Ph+ CR1 - MRD 6/3/2005 11 B ALL CR2 - MRD 352 11/22/2007
Cord 10 AML CR1 - MRD 3/5/2007 42 ALL Ph+ CR1 6/16/2008 42 T ALL CR2/aplastic 426 6/11/2007
MMURD 26 AML CR1 - MRD 2/1/2008 43 ALL Ph+ CR1 8/18/2006 25 T ALL CR2/aplastic 396 1/14/2004
MURD 5 AML CR1 - MRD 12/22/2003 41 ALL Ph+ CR1 1/7/2005 40 B ALL CR2 334 11/20/2001
Cord 13 CML CP2 s/p BC 4/12/2007 11 ALL Ph+ CR1 12/12/2006 15 B ALL CR3 - MRD 1389 5/8/2008
MMURD 29 CML CP2 s/p BC 12/14/2004 6 ALL Ph+ CR1 3/22/2005 11 B ALL CR3 - MRD 1127 8/7/2003
MURD 24 CML CP2 s/p BC 5/2/2006 28 ALL Ph+ CR1 10/20/2006 11 B ALL CR3 2009 3/4/2003
Cord 24 CML CP1 7/20/2007
MMURD 17 CML CP1 8/8/2003
MURD 22 CML CP1 12/19/2003
MURD indicates matched unrelated donor; MMURD, mismatched unrelated donor; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid myelogenous leukemia; CR1, first
complete remission; CP1, first chronic phase; Ph+, Philadelphia chromosome; MRD, minimal residual disease.
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Biol Blood Marrow Transplant 15:1122-1129, 2009 1125Low Relapse without TRM following Myeloablative CBTNovember 2001 and November 2007 (median May
2005). Conditioning regimen were: 120 mg/kg Cy
and 12 Gy TBI (n5 12); 120 mg/kg CY, and 13.2 Gy
TBI (n5 9); 120 mg/kg CY and oral busulfan (Bu)
targeted (targeted Bu) to 800-900 ng/mL (n5 4);
targeted Cy and 12 GyTBI (n5 2); 42 g/m2 treosulfan
(TREO), and 150 mg/kg Flu (n5 2); targeted Bu,
120 mg/m2 Flu, and 5.5 mg/kg antithymocyte globulin
(ATG) (n5 1); 95 mg/kgCy and 12 GyTBI (decreased
Cy for a patient with a history of liver abnormalities)
(n5 1). GVHDprophylaxis was CsA andmethotrexate
(MTX) (n5 11), tacrolimus (TAC), and MTX
(n5 17), and TAC, sirolimus, and MTX (n5 3).
Among MMURD patients, transplants occurred
betweenOctober 2002 andFebruary 2008 (medianDe-
cember 2004).Conditioning regimenswere: 120 mg/kg
Cy and12 GyTBI (n5 12); 120 mg/kgCy and13.2 Gy
TBI (n5 7); 120 mg/kgCyand targetedBu (n5 9); tar-
geted Cy and 12 Gy TBI (n5 1); 120 mg/kg Cy, tar-
geted Bu, and ATG 4.5 mg/kg (n5 1); 60 mg/kg
etoposide and 12 Gy TBI (etoposide substituted for
Cy for a patient with borderline ejection fraction)
(n5 1). GVHD prophylaxis was CsA and MTX
(n5 17), and TAC and MTX (n5 14).
Statistical Analysis
Patient characteristics and follow-up times are
summarized using standard measures. Cumulative
incidence estimates of acute GVHD (aGVHD) and
cGVHD, relapse, and TRM were utilized, with death
or relapse (forGVHD), TRM (for relapse), and relapse
(for TRM) included as competing risk events [17].
Relapse was defined as the presence of .5% morpho-
logic marrow blasts or biopsy proven extramedullary
disease. aGVHD was graded according to established
criteria [18]. cGVHD was graded according to the
2005 National Institutes of Health (NIH) consensus
criteria [19]. Kaplan-Meier estimates were used to
evaluate overall survival (OS) and relapse-free survival
(RFS). Censoring for all time-to event outcomes
occurred at the date of last contact. Estimates are
reported at 2 years post-HCT because the maximum
follow-up time for the cord blood group was 2.7 years
and no deaths or relapses occurred after 2 years in any
group. Associated 95% confidence intervals (CIs) are
reported for each incidence estimate. Cause-specific
hazards are compared between groups using a log
rank test, with 2-sided P-values considered significant
at the .05 level.RESULTS
Matching
All patients were matched successfully for all
disease criteria, except in the following 3 cases
(Table 2): a CBT patient with ALL was in CR1 withMRD (0.05% blasts by flow cytometry), whereas the
MMURD matched pair had no MRD; a CBT patient
with ALLwas in CR3withMRD (0.01% blasts by flow
cytometry and cytogenetic abnormalities), whereas the
MURD matched pair had no MRD; and an MMURD
ALL patient in CR1 had MRD (flow cytometry nega-
tive, cytogenetic positive), whereas the CBT patient
had no MRD. For patients with acute leukemias in
CR1 at the time of transplant, median time from diag-
nosis to transplant was 177 days for CBT patients
(range: 90-416 days), 151 days for MURD patients
(range: 106-300 days), and 186 days for MMURD pa-
tients (range: 113-364 days). The 6 patients with either
CMLor Philadelphia chromosome-positive ALLwere
all treated with imatinib prior to transplant. Four of 6
patients in the CBT, MURD, and MMURD cohorts
were treated with imatinib posttransplant. Median
age difference was 3 years between CBT and MURD
pairs and 5 years between CBT and MMURD pairs.
Median follow-up for surviving CBT patients is 21.1
months (range: 6.6-32.6 months) versus 35.1 months
(range: 12.4-75.8 months) for MURD patients and
29.1 months (range: 7-65.1 months) for MMURD
patients.Relapse
There has been 1 relapse among cord patients ver-
sus 8 relapses among MURD patients and 7 relapses
among MMURD patients. Two-year cumulative inci-
dence of relapse is 3.2%, 95%CI [0.2-14.1%] for CBT
patients versus 25.8%, 95% CI [12.1-41.8%] for
MURD patients and 23%, 95% CI [10.1-38.9%] for
MMURD patients (Table 3, Figure 1). Cause-specific
hazard for relapse is significantly decreased when com-
paring cord patients to MURD patients (P5 .018) and
MMURD patients (P5 .019) by log rank test.TRM
There have been 6 deaths because of TRM
among CBT patients versus 5 among MURD pa-
tients and 9 among MMURD patients. Causes of
TRM among CBT patients were infection (n5 5)
and GVHD (n5 1), among MURD patients were in-
fection (n5 3), GVHD (n5 1), and regimen-related
toxicity (RRT; n5 1), and among MMURD patients
were infection (n5 3), GVHD (n5 3), RRT (n5 2),
and GVHD/infection (n5 1). Two-year cumulative
incidence of TRM is 20.6%, 95% CI [8.2-36.9%]
for CBT patients versus 17%, 95% CI [6.2-32.5%]
for MURD patients and 29.2%, 95% CI [14.6-
45.5%] for MMURD patients (Table 3, Figure 1).
Cause-pecific hazard for TRM is nonsignificant
when comparing CBT patients to MURD patients
(P5 .78) and MMURD patients (P5 .41) by log
rank test.
Table 3. Relapse, TRM, and Survival
Two Year
Cumulative Incidence (95% CI)
Transplant Type Relapse TRM
Cord blood 3.2% (0.2%, 14.1%) 20.6% (8.2%, 36.9%)
MMURD 23.0% (10.1%, 38.9%) 29.2% (14.6%, 45.5%)
MURD 25.8% (12.1%, 41.8%) 17.0% (6.2%, 32.5%)
Two Year
Survival (95% CI)
Transplant Type Overall Survival Relapse-Free Survival
Cord blood 74.5% (53.0%, 87.2%) 76.2% (56.0%, 88.0%)
MMURD 50.0% (31.0%, 66.2%) 47.8% (29.5%, 64.0%)
MURD 59.7% (39.8%, 74.9%) 57.1% (37.7%, 72.5%)
1126 Biol Blood Marrow Transplant 15:1122-1129, 2009J. A. Gutman et al.GVHD
Cumulative incidence of grade II-IV aGVHD
through day 100 among CBT patients is 80.6%,
95% CI [61.9%- 90.8%] versus 67.7%, 95%
[48.4%, 81.2%] for MURD patients and 87.1%,
95% CI [69.2%, 95.0%] for MMURD patients.
Cumulative incidence of grade III-IV aGVHD
among CBT patients is 29.0%, 95% CI [14.5%-
45.3%] versus 12.9%, 95% CI [4.1%-27.0%] for
MURD patients and 35.5%, 95% CI [19.4%-
51.9%] for MMURD patients. Two-year incidence
of the composite endpoint of equal to or greater
than moderate cGVHD or grade II-IV late, persis-
tent or relapsing aGVHD, or overlap syndrome is
56.5%, 95% CI [37.0%, 72.1%] for CBT patients
versus 49.2%, 95% CI [30.6%-65.3%] for MURD
patients and 48.5%, 95% CI [29.8%-65.4%] for
MMURD patients (Figure 2). Among CBT patients,
only 3 patients with late GVHD developed equal to
or greater than moderate cGVHD; 14 patients had
late, persistent, or relapsing aGVHD. No cumulative
incidences of GVHD are statistically significantly de-
creased or increased when comparing CBT patients
to MURD or MMURD patients.||||||||||||||||
|
||| ||||||
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Figure 1. Cumulative incidence of relapse andOS and RFS
Two-year OS and RFS for CBT patients are
74.5%, 95% CI [53-87.2%] and 76.2%, 95% CI
[56-88%] versus 59.7%, 95% CI [39.8-74.9%] and
57.1, 95% CI [37.7-72.5%] for MURD patients and
50%, 95% CI [31-66.2%] and 47.8%, 95% CI
[29.5-65%] for MMURD patients (Table 3, Figure 3).
Cause-specific hazard for OS and RFS are borderline
significantly decreased when comparing CBT
patients to MMURD patients (P5 .062 and .041,
respectively) and nonsignificant when comparing
CBT patients to MURD patients (P5 .27 and .17,
respectively).DISCUSSION
We have observed a low relapse rate following MA
CBT for patients with high-risk acute leukemias or
CML in morphologic CR at the time of transplant. A
number of factors might contribute to this low relapse
rate. The majority of patients in our study (n5 22) un-
derwent double-unit CBT with 2 unmanipulated units
and 6 additional patients underwent double-unit CBT
with 1 unmanipulated and 1 CD341 selected and ex
vivo expanded unit. Clinical data suggest that for pa-
tients with good disease control at the time of trans-
plant, double-unit CBT may be associated with
decreased relapse rates [3,15,16]. The biologic mecha-
nism underlying this observation is not characterized,
but it may be a result of the immunologic interaction
between the 2 units and the host and is an area of active
investigation. Additionally, the majority of our CBT
patients underwent transplant with multiply mis-
matched units; only 1 patient received 6/6 matched
units. In the unrelated donor setting, higher degrees
of mismatch are associated with lower relapse risk,
but increased TRM, and early data also support this
observation in the CBT setting [10]. It is uncertain
whether a higher proportion of patients with better
matched cord blood units would result in higher rates|||||||
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Figure 2. Cumulative incidence GVHD by cohort. Grade II-IV GVHD through day 100 (A), grade III-IV GVHD through day 100 (B), and composite
endpoint of equal to or greater than moderate cGVHD or grade II-IV late, persistent, or relapsing aGVHD (C).
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adult patients contains 13.2 Gy TBI. Many TBI based
MA noncord blood HCT conditioning regimens for
adults, including those at our center, contain 12 Gy
TBI. Fifteen patients in the MURD cohort and 14 pa-
tients in the MMURD cohort received only 12 Gy
TBI. Higher TBI doses are associated with decreased
relapse, although they have also been associated with
increases in TRM [20,21].
To compare this relapse rate to the relapse rate
observed in comparable patients undergoing MA
MURD and MMURD transplants, we conducted
a matched cohort analysis. Because details of the dis-
ease and disease status at the time of transplant are
the most important predictors of relapse risk, we0.00
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Figure 3. OS and RFS. Kaplan-Meier efocused on matching patients very closely for these
variables. Our center’s large database of MURD and
MMURD transplants allowed us to match comparably
aged patients who had undergone transplants in a com-
parable period and received similar supportive care. In
the MURD cohort there were 8 relapses and in the
MMURD cohort there were 7 relapses, in contrast
to 1 relapse in the cord group. The lack of difference
in relapse rates between the MURD and MMURD
cohorts is likely attributable to the small sample size,
but it is possible that unidentified risk factors for
relapse in the MMURD cohort may contribute to
this finding.
Although the small size of our series precludes
definitive conclusions, the homogeneity of the cohorts0.00
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1128 Biol Blood Marrow Transplant 15:1122-1129, 2009J. A. Gutman et al.is important. In larger series of CBT outcomes that
have included analysis of relapse rates, many patients
are not in morphologic remission at the time of trans-
plant. Moreover, for larger series, disease risk is
typically stratified into early (CR1), intermediate
($CR2), and advanced (morphologic relapse)
[9,12,14,22]. The advent of MRD monitoring and
increasing refinement of cytogenetic and molecular
risk markers for prognosis of acute leukemias allows
increasingly sophisticated stratification of relapse risk
assessment, and data supports the observation that
poor risk features, even for patients in morphologic
CR at the time of transplant, increase the chance of
posttransplant relapse [23-30]. Although many reports
comparing outcomes between single-unit CBT and
MURD or MMURD HCT find comparable relapse
rates even when comparing patients in CR at the
time of transplant, it is possible that bias exists. CBT
is often reserved for patients with the highest risk dis-
ease and is frequently undertaken when transplant is
felt to be urgent. These patients, although they may
be in CR, may have disease features putting them at
greater risk for relapse than patients undergoing
URD transplant. Alternatively, however, investigators
fearing less GVL effects with cord blood may reserve
the technique for those at lower risk.
Importantly, nonrelapse-related outcomes were
comparable between cohorts. Regarding GVHD, our
observed high incidence of grade II-IV aGVHD
among CBT patients is consistent with recent reports
suggesting that double-unit CBT is associated with
a higher incidence of aGVHD than single unit CBT
[4,5]. In contrast to other reports regarding cGVHD,
however, we have observed a relatively higher inci-
dence of the composite endpoint of equal to or greater
than moderate cGVHD or grade II-IV late, persistent,
or relapsing aGVHD, or overlap syndrome in our
CBT patients. The majority of CBT patients
experiencing this composite endpoint had either late,
persistent, or relapsing aGVHD; only 3 patients dem-
onstrated features of equal to or greater than moderate
cGVHD. Few studies have graded cGVHD according
to the 2005 NIH consensus criteria, and the extent to
which late manifestations of GVHD among CBT pa-
tients may be different from late manifestations of
GVHD in other donor settings requires further inves-
tigation. In addition, the prognostic significance of
late, persistent, or relapsing aGVHD versus classic
cGVHD is uncertain. Larger numbers and longer fol-
low-up will be needed to examine these issues. When
comparing the incidence of late GVHD between the
CBT, MURD, and MMURD cohorts in this study,
it is important to note that the low incidence of the
competing risk of relapse among CBT patients may
have resulted in an increased cumulative incidence of
late GVHD relative to the MURD and MMURD
cohorts.With respect to TRM, all patients were compara-
bly aged and underwent MA conditioning, indicating
good performance status and limited comorbidities
and decreasing the likelihood of selection bias affect-
ing TRM. Although delayed engraftment and immune
reconstitution remain important issues following CBT
and CBT patients frequently require intensive sup-
portive care in the early posttransplant period, we
did not observe excess TRM in our small cohort of
CBT patients.
Our data suggest that patients undergoing MA
CBT for high-risk acute leukemias in morphologic
CR have low relapse rates with acceptable TRM. The
use of double-unit transplants may contribute to these
results. These data suggest that consideration should
be given to proceeding rapidly to transplants with
CBT for patients with high-risk malignancies while
disease status is under good control. Although our se-
ries is small, and these findings may not hold true for
patients in relapse at the time of transplant or for older
or infirm patients unable to tolerate MA conditioning,
they do support increased investigation of CBT.
Larger numbers and longer follow-upwill be necessary
to confirm these observations.ACKNOWLEDGMENTS
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